Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
| Descriptor ID |
D000964
|
| MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 5 | 3 | 8 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 3 | 6 |
| 2000 | 5 | 0 | 5 |
| 2001 | 5 | 2 | 7 |
| 2002 | 14 | 0 | 14 |
| 2003 | 4 | 1 | 5 |
| 2004 | 6 | 4 | 10 |
| 2005 | 2 | 3 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 2 | 5 |
| 2008 | 5 | 3 | 8 |
| 2009 | 5 | 6 | 11 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 4 | 7 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 5 | 2 | 7 |
| 2017 | 5 | 2 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
-
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
-
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292.
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
-
Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
-
Drug eruptions associated with tumor therapy: Great imitators. Clin Dermatol. 2020 Mar - Apr; 38(2):208-215.
-
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
-
Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
-
Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2018 09 15; 24(10):2135-2141.
-
Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation. Chem Biol Interact. 2018 Dec 25; 296:1-8.